ContraFect Corporation Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA

YONKERS, NY–(Marketwired – Apr 29, 2015) – ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced that it has commenced screening of healthy volunteers in its Phase 1 clinical trial of CF-301. CF-301 is being developed to be used in combination with standard of care antibiotics for the treatment of Staph bloodstream infections, including infective endocarditis, caused by drug-sensitive and drug-resistant Staph aureus.

This entry was posted in Recent Developments. Bookmark the permalink.
Read Full Article »